Qualitas has been studying the stability of its algal oil compared to that of krill oil.
Algae supplier Qualitas (Imperial, TX) announced launch of the first commercial products featuring its EPA-rich, algae-derived Almega PL omega-3 ingredient. This is a milestone for the company, which spent the last 18 months transitioning from the R&D stage to commercial production.
The new products featuring Almega PL are a supplement from doctor-brand Healthy Directions, marketed as a 100%-vegetarian omega-3 oil for heart health, mood, and general well-being, and the Veggie Omega-3+ supplement from Rejuvenation Science Labs, which contains Almega PL, algal DHA, and astaxanthin. The brands point to Almega PL’s higher bioavailability, with Healthy Directions stating that “Almega PL’s high bioavailability comes from its unique molecular structure of phospholipids and glycolipids. In fact, it’s suggested that glycolipids, which are not found in krill, are more effective than phospholipids at delivering EPA into the cells.”
Qualitas has been studying the stability of its algal oil compared to that of krill oil. Earlier this year, the company reported superior stability of its ingredient, thanks to the ingredient’s unique polar-lipid structure, combination of phospholipids and glycolipids, and the presence of naturally occurring zeaxanthin and carotenoids in algae.
The company is now opening Almega PL production from Nannochloropsis oculata algae to the rest of the supplements industry. “Qualitas Health has emerged as the first company manufacturing omega-3 nutrition ingredients using phototropic algae technology to successfully commercialize,” the company said via press release. It also proposes blending Almega PL with other algae ingredients “to create a vegetarian and sustainable alternative to fish or krill oils.”
This summer, the company also announced it filed a new dietary ingredient (NDI) notification for Almega PL.
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine jennifer.grebow@ubm.com
Photo © iStockphoto.com/buccaneership
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.